Parents' and guardians' views on the acceptability of a future COVID-19 vaccine: A multi-methods study in England

The availability of a COVID-19 vaccine has been heralded as the key to controlling the -19 pandemic. Success will rely on public willingness to be vaccinated, according to a new study. The study looked at how COVID-19 vaccines are developed and tested, including their safety and efficacy. It identified factors that may affect vaccine acceptability in ethnic minority and lower-income groups who are disproportionately affected by the vaccine.

Evaluation of COVID-19 Vaccine Refusal in Parents

The aim of the study was to predict the frequency of vaccine refusal against domestic and foreign COVID-19 vaccines. The most common reasons for refusal were anxiety about vaccine side effects, lack of knowledge about the effectiveness of vaccines, and distrust of vaccines originating from abroad. This study demonstrates that vaccine uptake can be increased by considering the higher preference for domestic vaccines.

Viral targets for vaccines against COVID-19

Vaccines are urgently needed to control the coronavirus disease 2019 (COVID-19) pandemic. Several vaccine candidates are being developed, several of which have completed late-stage clinical trials and are reporting positive results. The aim is to help them return to pre-pandemic normalcy.

COVID-19 vaccine: where are we now and where should we go?

The coronavirus-2 (SARS-CoV-2) has created a potentially fatal disease, coronaviruses disease-2019 (COVID-19) Despite the continuous efforts of researchers to find effective vaccines and drugs for COVID-20, there is still no success. The literature regarding the vaccine candidates currently in the clinical trials, as well as main candidates in pre-clinical stages for development and research, were reviewed. There are several limitations in the field of rapid vaccine development against SARS-CoV-

Clinical Outcomes Of A COVID-19 Vaccine: Implementation Over Efficacy

The global effort to develop a coronavirus disease 2019 (COVID-19) vaccine is on track to produce one or more vaccines. The benefits of a vaccine will decline substantially in the event of manufacturing or deployment delays, vaccine hesitancy, or greater epidemic severity.

COVID-19 and Vaccine Hesitancy: A Challenge the United States Must Overcome

A significant portion of the U.S. population may experience vaccine hesitancy of a new COVID-19 vaccine. This poses dangers to both the individual and their community, since exposure to a contagious disease places the person at risk, and individuals are far more likely to spread the disease to others if they do not get vaccinated. Experience from the influenza vaccines has shown vaccine acceptance has not been optimal, and this new vaccine, even though it is not approved, is already showing layp

Efforts towards a COVID-19 vaccine

The development of a vaccine against SARS coronavirus 2 (SARS-CoV-2) will be the way to restore normality to civil life in this time of a devastating pandemic. As of mid-August 2020, more than 20 million people have been infected and more than 760 000 lives have been lost worldwide. There are many vaccine candidates in development, including preclinical and clinical testing.

COVID-19 vaccine development: What lessons can we learn from TB?

The SARS-CoV-2 virus has infected more than 49 million people causing more than 1.2 million deaths worldwide since its emergence from Wuhan, China in December 2019. Tuberculosis is also a major infectious respiratory disease of the worldwide prevalence and vaccine development for tuberculosis has been ongoing for decades. we highlight some of the common features, challenges, and complications in tuberculosis vaccine development, which may also be relevant for, and inform COVID-19 vaccine develop

Departments

Recent Posts